NCT02053818

Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.

Fast-track in Cardiac Surgery. Remifentanyl & Sufentanil Anaesthesia for CABG+/-AVR Evaluated by Recovery, Cognitive Dysfunction, Haemodynamics (PAC/TTE) and Cardiac Biochemical Markers (CKMB, TNT, Pro-BNP)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Aarhus University Hospital · Academic / Other
• Sex: All
• Age: 60 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effect on cognitive function, recovery, cardioprotection and haemodynamics of standard Remifentanil anaesthesia to standard Sufentanil anaesthesia in patients undergoing coronary artery bypass with or without aortic valve replacement.

Detailed description

1. Haemodynamic effects, evaluated by invasive haemodynamic data (arterial line and PAC) of opioid given as single drug and in combination with Propofol (first 30 patients only). 2. Cognitive dysfunction evaluated by standard test preoperative and postoperative day 1, 4 and 30 3. Recovery quality and time parameters using objective ICU score criteria 4. Cardioprotection effect evaluated by myocardial biochemical markers obtained preoperative and postoperative 4, 9 and 18 hours

Conditions

• Ischaemic Heart Disease
• Aortic Stenosis

Interventions

Type	Name	Description
DRUG	Remifentanil	Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
DRUG	Sufentanil	Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia

Timeline

• Start date: 2011-08-01
• Primary completion: 2015-06-01
• Completion: 2015-08-01
• First posted: 2014-02-04
• Last updated: 2015-08-13

Locations

1 site across 1 country: Denmark